Latest News

blood cells on a light blue background
Obe-Cel Approval Was a ‘Major Milestone’ for ALL Treatment

November 29th 2024

An expert discusses the FDA approval of obecabtagene autoleucel—the only CAR T-cell therapy given via split dosing for patients with ALL.

blood cells on a yellow background
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma

November 11th 2024

blood cells. onblue background
Real-World Data Show Efficacy of Brexu-Cel, ICANS Concerns

November 5th 2024

CAR T-cells
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma

November 4th 2024

person pointing finger at FDA
October 2024 FDA Approvals for Oncology

October 30th 2024

Video Series
Video Interviews
Podcasts
The Vitals
The Vitals
Oncology Nursing News
Oncology Nursing Stories: Pregnancy After Lymphoma Chemoradiation
Stephanie Jackson Unpacks Recent Advances in Leukemia Treatments
When an Oncology Nurse Becomes a Cancer Mom: How One Nurse Navigated Her Child’s Leukemia Diagnosis
Latest CME Events & Activities

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.